演題詳細

一般口演 / Oral Session

一般口演 11 (Oral Session 11) :低悪性度B細胞リンパ腫:治療研究

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
小宅 達郎 (Tatsuo Oyake):1
1:岩手医科大学 血液・腫瘍内科
 
前へ戻る

Retrospective analysis of Radioimmunotherapy with 90Y-ibritumomab tiuxetan

演題番号 : OS-1-55

堺 寿保 (Toshiyasu Sakai):1、三宅 奏衣 (Kanae Miyake):1、津下 奈都子 (Natsuko Tsushita):1、宮尾 康太郎 (Kotaro Miyao):1、酒村 玲央奈 (Reona Sakemura):1、加藤 智則 (Tomonori Kato):1、新美 圭子 (Keiko Niimi):1、小野 芳孝 (Yoshitaka Ono):1、澤 正史 (Masashi Sawa):1

1:Department of Hematology and Oncology, Anjo Kousei Hospital, Japan

 

Back ground:Radioimmunotherapy(RIT) with 90Y-ibritumomab tiuxetan has been used for the treatment of relapsed or refractory indolent B-cell lymphoma. This study evaluated efficacy and safety of RIT in our institute, retrospectively.
Methods and patients:From October 2009 to February 2013, 19 patients were treated with RIT. Histology was as follow: FL 18 cases, MCL 1 case. Median age was 68 (range 53-82) .Median the longest tumor mass was 2.5cm (range1.0-5.0). Median number of prior regimens was 4 (range 1-12).
Result:Median follow-up was 747 days (range5-1401). The overall response rate (ORR) was 55% (CR:39% PR17%).Median progression free survival (PFS) and time to next treatment (TTNT) were 237 days (54-420) and 330 days (230-431), respectively. Prognostic factor for ORR was the longest tumor mass<2.0cm.(P=0.03). Prognostic factor for OS in univariate analysis ware age<70yr (P=0.01) and patients with CR+PR (P<0.01). But in multivariate analysis, we found no significant prognostic factor for OS. For PFS , prognostic factors in multivariate analysis were prior regimen of auto PBSCT (P=0.02) and patients with CR+PR (P<0.01)
Discussion:Our treatment results of RIT was equal those of previous reports. Thomas et al revealed RIT was more effective for non bulky disease (the longest tumor mass<5.0cm). Our study suggest RIT is effective at patients with smaller mass than we thought.

前へ戻る